50 results
8-K
EX-99.1
KA
Kineta Inc
15 May 24
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
4:03pm
corporate restructuring to substantially reduce expenses and preserve cash. The restructuring included a significant workforce reduction
8-K
EX-99.1
KA
Kineta Inc
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
to substantially reduce expenses and preserve cash. The restructuring included a significant workforce reduction and the suspension of enrollment of new … a workforce reduction of the Company’s workforce of approximately 64% of the Company’s then-current employee base.
2023 FINANCIAL HIGHLIGHTS
Cash
8-K
jvpqtg3byhsisf3y7z
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-99.1
7iv3ja kko
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
8-K
5hckeph4vizf 53x
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
8-K
EX-99.5
0nr7 nun6
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.3
n6un6v
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
zcb2ramn
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.4
a5gqmnt89wg3sh
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
424B3
hhfg0icg4 q7
5 Dec 22
Prospectus supplement
9:22am
424B3
b2nq xwmy
10 Nov 22
Prospectus supplement
4:21pm